drugset / Trial / NCT01332630
TPI 287 in Breast Cancer Metastatic to the Brain
NaSingle-groupOpen-labelTreatment
Summary
The goal of the first part of this clinical research study is to find the highest tolerable dose of TPI-287 in patients with breast cancer that has spread to the brain. The goal of the second part of this study is to learn if TPI-287 can control breast cancer that has spread to the brain. The safety of this drug will also be studied.
Timeline
- Start
- 2011-08-16
- Primary completion
- 2017-04-14
- Completion
- 2017-04-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TPI 287 | Small molecule | 160 mg/m2 | Intravenous |
| Background | Dexamethasone | Small molecule | 6 mg | Oral |
| Background | Dexamethasone | Small molecule | 10 mg | Oral |
| Background | Diphenhydramine | Unknown | 12.5 mg | Intravenous |
| Background | Diphenhydramine | Unknown | 25 mg | Intravenous |
| Background | Ranitidine | Unknown | 1 mg/kg | Intravenous |